Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Colla

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2023
Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in <i>RAS</i> -mutated chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Feiyang Ma, Natthakan Thongon, et al.
Nature Communications|March 19, 2024
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromesJuan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Feiyang Ma, et al.
Nature|July 9, 2015
Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancerFlorian Muller, Simona Colla, Elisa Aquilanti, et al.
Cell Reports. Medicine|May 23, 2024
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Natthakan Thongon, Juan Jose Rodriguez-Sevilla, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
IL-1β-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromesVera Adema, Irene Ganan-Gomez, Feiyang Ma, et al.
The Lancet. Haematology|September 5, 2022
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 studyAlexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
Blood Advances|March 24, 2019
<i>NPM1</i> mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, et al.
Nature|August 17, 2012
Passenger deletions generate therapeutic vulnerabilities in cancerFlorian L Muller, Simona Colla, Elisa Aquilanti, et al.
Leukemia|March 12, 2024
STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon responseBhakti Patel, Yifan Zhou, Rachel L Babcock, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2023
Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in <i>RAS</i> -mutated chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Feiyang Ma, Natthakan Thongon, et al.
Nature Communications|March 19, 2024
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromesJuan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Feiyang Ma, et al.
Nature|July 9, 2015
Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancerFlorian Muller, Simona Colla, Elisa Aquilanti, et al.
Cell Reports. Medicine|May 23, 2024
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Natthakan Thongon, Juan Jose Rodriguez-Sevilla, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
IL-1β-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromesVera Adema, Irene Ganan-Gomez, Feiyang Ma, et al.
The Lancet. Haematology|September 5, 2022
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 studyAlexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
Blood Advances|March 24, 2019
<i>NPM1</i> mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, et al.
Nature|August 17, 2012
Passenger deletions generate therapeutic vulnerabilities in cancerFlorian L Muller, Simona Colla, Elisa Aquilanti, et al.
Leukemia|March 12, 2024
STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon responseBhakti Patel, Yifan Zhou, Rachel L Babcock, et al.
Pageof 10